Hrt Financial LP Tg Therapeutics, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$6.68 - $18.81 $511,307 - $1.44 Million	76,543 New	76,543 $1.31 Million
Q2 2023 Aug 11, 2023	SELL	$15.48 - $35.0 $2.91 Million - $6.58 Million	-188,044 Reduced 90.01%	20,868 $518,000
Q1 2023 May 12, 2023	BUY	$10.23 - $19.34 $485,433 - $917,721	47,452 Added 29.39%	208,912 $3.14 Million
Q4 2022 Feb 10, 2023	BUY	$5.01 - $11.83 $378,169 - $892,963	75,483 Added 87.79%	161,460 $1.91 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $392,914 - $722,206	85,977 New	85,977 $508,000
Q4 2019 Feb 14, 2020	SELL	$5.1 - $11.2 $65,759 - $144,412	-12,894 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $69,369 - $115,917	12,894 New	12,894 $72,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.